分子標的治療薬を含むがん化学療法施行中の口腔内有害事象発症例の検討  [in Japanese] Clinical Observation of the Patients with Oral Adverse Events During Cancer Chemotherapy Including Molecular Targeted Drugs  [in Japanese]

Access this Article

Search this Article

Author(s)

    • 秋山 薫 AKIYAMA Kaoru
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
    • 齋藤 正浩 SAITO Masahiro
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
    • 小宮山 雄介 KOMIYAMA Yuske
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
    • 土田 修史 TSUCHIDA Shuji
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
    • 大久保 真希 OKUBO Maki
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
    • 川又 均 KAWAMATA Hitoshi
    • 獨協医科大学医学部口腔外科学講座 Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine

Abstract

分子標的治療薬における口腔内有害事象についての詳細な報告は少ない。今回われわれは,がん化学療法中に発生した口腔内有害事象のうち,分子標的治療薬を使用していた症例について臨床的検討を行った。2007年4月から2014年3月までに口腔内有害事象にて口腔ケア外来を受診した患者のうち,分子標的治療薬を投与されていた27例 (23患者) について使用薬剤および口腔内有害事象の詳細について検討を行った。使用薬剤は低分子化合物10例,モノクローナル抗体薬17例であった。低分子化合物は全て単独使用であったが,モノクローナル抗体薬は殺細胞薬と併用されていた。口腔粘膜炎は27症例全例に認め,味覚障害は4例でみられた。全例口腔機能管理を行うことで対応可能であり治療期間の延期は認めなかった。使用薬剤のうちスニチニブ (マルチキナーゼ阻害薬) は,単独使用で口腔粘膜炎が生じており,使用前から積極的に口腔機能管理を行うことが必要であると考えられた。

There was a few study concerning the oral adverse events during cancer therapy with molecular targeted drugs. Among the patients referred to our oral care unit from April 2007 to March 2014, 23 patients who were treated with molecular targeted drugs showed 27 oral adverse events. We examined the details of the oral adverse events and the causal drugs on these 23 patients. Ten patients were treated with small molecule drugs, while 17 patients were treated with monoclonal antibody drugs. The small molecule drugs were used singly, whereas the monoclonal antibody drugs were always used with conventional cytotoxic chemotherapeutic agents. Oral mucositis was observed in all 23 patients (27 events), and taste disorder was seen in 4 patients (4 events). All patients received the professional oral management, then they completed their cancer chemotherapy in the designated period. Because the single use of sunitinib (multi-kinase inhibitor) could lead oral mucositis, an intensive oral management before sunitinib treatment should be necessary.

Journal

  • Journal of Japanese Society of Oral Medicine

    Journal of Japanese Society of Oral Medicine 22(1), 1-7, 2016

    Japanese Society of Oral Medicine

Codes

  • NII Article ID (NAID)
    130006909065
  • NII NACSIS-CAT ID (NCID)
    AA1257777X
  • Text Lang
    JPN
  • ISSN
    2186-6147
  • NDL Article ID
    027502147
  • NDL Call No.
    Z19-B696
  • Data Source
    NDL  J-STAGE 
Page Top